Original contributionEffects of metalloporphyrin catalytic antioxidants in experimental brain ischemia
Introduction
Reactive oxygen and nitrogen species play critical roles in the response of brain to an ischemic insult [1]. Renewed interest in therapeutic application of antioxidants has been derived from three independent sources of information. First, hydroxyl radical production persists for at least several hours after onset of ischemia in rodent models, suggesting the potential for a clinically relevant therapeutic window [2], [3]. This is consistent with the observation that superoxide (O2−) production is sustained after reperfusion from middle cerebral artery occlusion (MCAO) [4], [5]. Second, investigations with transgenic mice have demonstrated consistent improvement of histologic/neurologic outcome from either focal or global ischemia when overexpression of either copper/zinc (CuZn-SOD), manganese (Mn-SOD) [6] or extracellular (EC-SOD) superoxide dismutase is achieved [7], [8], [9]. Conversely, targeted 2deletion of the Mn-SOD [10], CuZn-SOD [11], or EC-SOD isozymes [12] worsens ischemic outcome. Third, pharmacologic advances in synthesis of catalytic antioxidants have led to evaluation of such molecules in a variety of stroke models [13], [14], [15], [16]. Efficacy in reducing infarct size and neurologic deficit, despite a substantial delay in administration after onset of acute brain injury, has raised hope that compounds possessing this mechanism of action may find clinical utility.
A metalloporphyrin catalytic antioxidant has recently been shown to be effective in the modification of temporary focal ischemia in rodent models [16]. This metalloporphyrin, AEOL 10113 [17], [18], is limited by the fact that it is composed of several stereoisomers that make a pharmaceutically acceptable formulation difficult and severely limit the ability to assess tissue levels and carry out pharmacokinetic studies. AEOL 10150 is a structurally different metalloporphyrin catalytic antioxidant than AEOL 10113, which possesses imidizole side chain substitutions (Fig. 1). AEOL 10150 provides a nearly 2-fold increase in SOD potency compared to AEOL 10113 and reduces the IC50 for in vitro lipid peroxidation by 50% (Table 1). In contrast to AEOL 10113, AEOL 10150 does not exist as a stereoisomer, is relatively easy to synthesize, and can be accurately and simply analyzed in tissues [19]. We hypothesized that AEOL 10150 would yield neuroprotection equivalent to AEOL 10113 at doses markedly less than those required to produce neurotoxicity in a rat model of focal cerebral ischemia. The work was extended to define intravenous (i.v.) AEOL 10150 efficacy in a mouse MCAO model and to perform pharmacokinetic assessment of the transfer of AEOL 10150 from blood to brain under conditions of ischemia/reperfusion. We then sought to define interactions between AEOL 10150 and the proteomic response of brain to focal ischemia and probe mechanisms for the protection observed in primary mixed neuronal/glial cultures exposed to oxygen/glucose deprivation (OGD). We hypothesized that AEOL 10150 would reduce changes in protein expression attributable to ischemia, reduce neuronal cell death induced by oxidative stress in vitro, and preserve aconitase activity as a marker of superoxide mediated cell injury.
Section snippets
Materials and methods
The following studies were approved by the Duke University Animal Care and Use Committee.
Experiment one (relative behavioral neurotoxicity of AEOL 10113 vs. AEOL 10150)
For AEOL 10113, an i.c.v. dose of 600 ng was found to cause just noticeable behavioral side effects. For AEOL 10150, 9 μg was found to produce just noticeable behavioral effects. Thus, toxicity from AEOL 10150 was 1/15th that of AEOL 10113. We, therefore, studied an AEOL 10150 dose of 300 ng to provide direct comparison to AEOL 10113 and an AEOL 10150 dose of 4500 ng as a maximal dose clearly devoid of adverse behavioral effects.
Experiment two (rat MCAO/i.c.v. AEOL 10113 vs. AEOL 10150)
Physiologic values are given in Table 2. There were no
Discussion
The principal findings of this series of studies were as follows. Intracerebroventricular AEOL 10150 had 1/15th the potency of AEOL 10113 for inducing adverse neurobehavioral side effects in the rat. AEOL 10150 and AEOL 10113 had similar potency to reduce cerebral infarct size and neurologic deficit when given i.c.v. 90 min after reperfusion from MCAO. When given 6 h after reperfusion, AEOL 10150 reduced cerebral infarct volume by 43%. AEOL 10150 also reduced infarct size and neurologic deficit
Acknowledgements
This work was supported by U.S. Public Health Service grants R01 NS38944-03, U10 HL 63397, PO1 HL 31992, RO1 NS39587 and Incara Pharmaceuticals Corp., Research Triangle Park, NC, USA. Drs. Crapo, Day, and Warner hold an equity position in and serve as consultants for Incara, Inc. The authors are grateful to Ann D. Brinkhous for expert technical assistance.
References (38)
- et al.
Mice overexpressing extracellular superoxide dismutase have increased resistance to focal cerebral ischemia
Neuroscience
(1999) - et al.
Mice overexpressing extracellular superoxide dismutase have increased tolerance to global cerebral ischemia
Exp. Neurol
(2000) - et al.
Buckminsterfullerenol free radical scavengers reduce excitotoxic and apoptotic death of cultured cortical neurons
Neurobiol. Dis
(1996) - et al.
Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-069), a free radical trapping agent, in a rat model of hemorrhagic stroke
Neuropharmacology
(2001) - et al.
The ortho effect makes manganese(III) meso-tetrakis (N-methylpyridinium-2-yl)porphyrin (MnTM-2-Pyp5+) a powerful and potentially useful superoxide dismutase mimic
J. Biol. Chem
(1998) - et al.
Determination of cationic manganese (III) prophyrins using high-performance liquid chromatography with electrochemical detection
J. Chromatogr
(2002) - et al.
Influence of hypotension and hypotensive technique on the area of profound reduction in cerebral blood flow during focal cerebral ischaemia in the rat
Br. J. Anaesth
(1990) - et al.
Inactivation-reactivation of aconitase in Escherichia coli. A sensitive measure of superoxide radical
J. Biol. Chem
(1992) - et al.
Requirement for superoxide in excitotoxic cell death
Neuron
(1996) Spectrophotometric measurements of the enzymatic formation of fumaric and cis-aconitic acids
Biochem. Biophys. Acta
(1950)